SCHEMBL21713798

SCHEMBL21713798

CC(C)(C)OC(=O)N1CCC1CNS(=O)(=O)c1cccnc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.46
STS P08842 3/20 0.41
TGFBR1 P36897 5/20 0.40
KDM1A O60341 1/20 0.40
HPGD P15428 3/20 0.39
MAPT P10636 2/20 0.39
ALDH1A1 P00352 1/20 0.39
KDM4E B2RXH2 2/20 0.39
CNR2 P34972 1/20 0.39
TSHR P16473 1/20 0.39
IL1B P01584 1/20 0.39
P2RX7 Q99572 1/20 0.39
GPR119 Q8TDV5 2/20 0.38
APP P05067 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
DRD2 P14416 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
SLC6A2 P23975 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21714047 0.93 KDM1A (0.47) POLBSTSKDM1AHPGDMAPT
SCHEMBL29819176 0.93 KDM1A (0.47) POLBSTSKDM1AHPGDMAPT
SCHEMBL21713960 0.88 CNR2 (0.41) POLBSTSTGFBR1HPGDMAPT
SCHEMBL21713614 0.87 POLB (0.46) POLBSTSTGFBR1HPGDMAPT
SCHEMBL21713992 0.86 POLB (0.39) POLBSTSTGFBR1KDM1AHPGD
SCHEMBL21713810 0.85 HPGD (0.42) POLBHPGDMAPTALDH1A1CNR2
SCHEMBL21713417 0.82 PARP1 (0.53) POLBGPR119OPRK1
SCHEMBL21714012 0.79 DPP4 (0.45) POLBHPGDMAPTALDH1A1CNR2
SCHEMBL28574294 0.78 APP (0.46) POLBSTSKDM1AMAPTALDH1A1
SCHEMBL21714141 0.78 HPGD (0.45) POLBHPGDMAPTALDH1A1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4364804-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica NV (BE) 2024-05-08 EP disclosed
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2024-02-13 US disclosed
EP-3833662-B1 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2024-01-17 EP disclosed
EP-3833662-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica N.V. (BE) 2021-06-16 EP disclosed
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2021-03-16 US disclosed
WO-2020041169-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-27 WO disclosed
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2020-02-20 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 POLB 2535/4885STS 2248/4885TGFBR1 2836/4885
US-20200055874-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 POLB 2535/4885STS 2248/4885TGFBR1 2836/4885
US-10947252-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 POLB 2535/4885STS 2248/4885TGFBR1 2836/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.